Deal Tracker · Countries

Egypt pharma deals

27 pharma deals involving Egypt — companies based there or deals covering the market — tracked by EPT: localization, M&A & investment. Most active: Eva Pharma, Afreximbank, Rameda & VACSERA. Latest: Eva Pharma → Med Right (Partnership / Collaboration, 18 Nov 2026).

27
deals tracked
20
announced in 2026
$560.5m
disclosed value (5 deals)
30%
localization, the top deal type
  • EPT has tracked 27 Egypt pharma deals (2021–2026), 20 of them announced in 2026.
  • The most common structures are localization (30%), m&a (19%) & investment (15%).
  • Values were disclosed for 5 of 27 deals, totalling $560.5m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).
  • The most active companies: Eva Pharma (4), Afreximbank (2), Minapharm (2) & Rameda (2).

Most active companies

Eva Pharma (4) · Afreximbank (2) · Minapharm (2) · Rameda (2) · VACSERA (2)

Countries involved

Saudi Arabia (8) · UAE (6) · China (4) · Kuwait (4) · Bahrain (3) · Oman (3)

Largest disclosed deals

Questions

How many Egypt pharma deals has EPT tracked?
27 as of 18 Nov 2026, covering 2021–2026; 20 were announced in 2026. The most recent is Eva Pharma → Med Right (Partnership / Collaboration, 18 Nov 2026).
What types of Egypt pharma deals are most common?
Technology transfer / Localization: 8 (30%); M&A / Acquisition: 5 (19%); Equity / Investment: 4 (15%); Partnership / Collaboration: 4 (15%).
Which companies are most active in Egypt pharma deals?
Eva Pharma (4 deals), Afreximbank (2 deals), Minapharm (2 deals), Rameda (2 deals), VACSERA (2 deals).
What is the largest disclosed Egypt pharma deal?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Afreximbank → Med Aditus Pharmaceutical Kenya: $40m (Equity / Investment, 29 Nov 2024). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)